These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21324674)

  • 1. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
    Shapiro CL; Halabi S; Hars V; Archer L; Weckstein D; Kirshner J; Sikov W; Winer E; Burstein HJ; Hudis C; Isaacs C; Schilsky R; Paskett E
    Eur J Cancer; 2011 Mar; 47(5):683-9. PubMed ID: 21324674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
    Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
    Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
    Hershman DL; McMahon DJ; Crew KD; Cremers S; Irani D; Cucchiara G; Brafman L; Shane E
    J Clin Oncol; 2008 Oct; 26(29):4739-45. PubMed ID: 18711172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.
    Hershman DL; McMahon DJ; Crew KD; Shao T; Cremers S; Brafman L; Awad D; Shane E
    J Clin Endocrinol Metab; 2010 Feb; 95(2):559-66. PubMed ID: 20022990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
    Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
    Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
    Hines SL; Mincey B; Dentchev T; Sloan JA; Perez EA; Johnson DB; Schaefer PL; Alberts S; Liu H; Kahanic S; Mazurczak MA; Nikcevich DA; Loprinzi CL
    Breast Cancer Res Treat; 2009 Oct; 117(3):603-9. PubMed ID: 19214743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
    Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
    Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
    Furlanetto J; Marmé F; Seiler S; Thode C; Untch M; Schmatloch S; Schneeweiss A; Bassy M; Fasching PA; Strik D; Stickeler E; Schem C; Karn T; Grischke EM; Denkert C; van Mackelenbergh M; Müller V; Nekljudova V; Loibl S
    Eur J Cancer; 2021 Jul; 152():193-203. PubMed ID: 34116270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.
    Oostra DR; Lustberg MB; Reinbolt RE; Pan X; Wesolowski R; Shapiro CL
    Mol Cell Endocrinol; 2015 Feb; 402():51-6. PubMed ID: 25575458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.
    Leal T; Tevaarwerk A; Love R; Stewart J; Binkley N; Eickhoff J; Parrot B; Mulkerin D
    Clin Breast Cancer; 2010 Dec; 10(6):471-6. PubMed ID: 21147691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
    Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials.
    Mei M; Xiang Z; Yang J; Xiang R
    Curr Probl Cancer; 2020 Apr; 44(2):100507. PubMed ID: 31732237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial.
    Kyvernitakis I; Kann PH; Thomasius F; Hars O; Hadji P
    Bone; 2018 Sep; 114():109-115. PubMed ID: 29908297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer.
    Bertoldo F; Tonini G; Vincenzi B; Santini D
    Nat Rev Clin Oncol; 2009 Apr; 6(4):191-2. PubMed ID: 19333223
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.